Abeona to launch pivotal study of EB-101 in RDEB in mid-2019, new CF program launched; shares up 6% [Seeking Alpha]
Abeona Therapeutics Inc. (ABEO)
Last abeona therapeutics inc. earnings: 3/16 04:20 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.abeonatherapeutics.com
Company Research
Source: Seeking Alpha
Abeona Therapeutics ( ABEO ) is up on average volume following its pipeline update during its R&D Day. Highlights: A Phase 3 study, VITAL, evaluating lead candidate EB-101, a gene-corrected cell therapy, in recessive dystrophic epidermolysis bullosa (RDEB) will be launched in mid-2019. The primary endpoint will be the proportion of treated wounds with at least 50% healing at month 3. GMP manufacturing facility in Cleveland, OH, established for EB-101. The ongoing Phase 1/2 clinical trial evaluating ABO-102 in Sanfilippo syndrome type A (MPS IIIA) will be amended to include patients with earlier-stage disease. Substantial dose-related improvement in biomarkers have been observed. First program for its AIM vector platform, ABO-401, established for the potential treatment of cystic fibrosis (CF). The company says it is designed to correct the underlying CF chloride channel deficit regardless of CFTR mutation status. IND for ABO-202 in infantile Batten disease to be f
Show less
Read more
Impact Snapshot
Event Time:
ABEO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABEO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABEO alerts
High impacting Abeona Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
ABEO
News
- Abeona Therapeutics Inc (NASDAQ: ABEO) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.MarketBeat
- Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Here's Why We're Not Too Worried About Abeona Therapeutics' (NASDAQ:ABEO) Cash Burn Situation [Yahoo! Finance]Yahoo! Finance
- Abeona Therapeutics Reports Full Year 2023 Financial Results and Announces Completion of FDA Inspections [Yahoo! Finance]Yahoo! Finance
- Abeona Therapeutics Reports Full Year 2023 Financial Results and Announces Completion of FDA InspectionsGlobeNewswire
ABEO
Sec Filings
- 3/19/24 - Form DEF
- 3/18/24 - Form 8-K
- 3/18/24 - Form 10-K
- ABEO's page on the SEC website